global provider of customized laboratory and research services

News and Events

Making a difference in the fight against bladder cancer by lacing up your shoes

Global News: BLOGS September 19, 2016 12:57 pm

Dr. Alexandre Zlotta

A walk in the park this Sunday can make a difference against bladder cancer. This weekend you can make a difference in the fight against bladder cancer by participating in a walk to build awareness.

“It is a cancer that very few people know about,” said Dr. Alexandre Zlotta, Director of Uro-Oncology at Mount Sinai Hospital.

“It is the fourth most common cancer in men, and it is the most expensive cancer to treat per patient.”

Stephen Wilson is on the Board of Directors for Bladder Cancer Canada, a national charity organized to help patients and their support teams, increase awareness, and fund research.

He has a vested interest in the charity because three years ago, Wilson was diagnosed with bladder cancer.

“I had stage four bladder cancer,” said Wilson. “So a lot of the options that are available to some people to preserve the bladder were not available to me.”

“Not all patients are eligible for bladder preservation, but there have been truly amazing improvements in the last decade, very recently immunotherapy,” said Zlotta.

“We have started a dedicated clinic for bladder cancer where patients are offered different types of therapies, including ways that we could preserve the bladder with a combination of resection of the tumor, chemotherapy and radiation therapy. It opens completely new avenues for the patients and has improved their options.”

Zlotta said he thinks they could have a major impact on the disease, but everyone needs to work together.

“Without the walk, we would not be able to support the patients that [Zlotta] has,” said Wilson.

“We would not be able to fund research that he and other urologists use throughout Canada.”

Mount Sinai Services Inc. Announces Partnership with Personalis to Offer its ACE Platform for Next Generation Sequencing and Interpretation to Support Tumor Molecular Profiling and Immuno-Oncology Clinical Trials in Canada

Toronto, Ontario – June 07, 2016 – Mount Sinai Services, Inc. of Toronto, Ontario, Canada, a global provider of customized clinical laboratory and research services announced today that the company has entered into a letter of intent (LOI) with Personalis, Inc., a leading precision medicine company focused on advanced NGS-based clinical diagnostic and research services.  The LOI contains broad terms for the development of a partnership framework for Personalis and Mount Sinai Services to offer the Personalis patented, and CLIA validated ACE (Accuracy and Content Enhanced) sequencing and analysis technology for clinical diagnostic and research tumor molecular profile sequencing and analysis and immuno-oncology sequencing clinical trials for customers throughout Canada.  The ACE Platform® incorporates proprietary sample prep and sequencing processes which produce the highest levels of gene finishing and coverage of difficult-to-sequence regions.

Read more

 

Mount Sinai Services Achieved CAP Accreditation

Mount Sinai Services Inc. (MSS) an Independent Clinical Research Laboratory Achieves CAP Accreditation. We are pleased to announce that the Mount Sinai Services Inc. (MSS) laboratory has successfully achieved CAP accreditation On March 7th 2016.  MSS is one of very few independent clinical research laboratories to achieve […]

Read more

MSS receives ISO 15189 accreditation

We are pleased to announce that the Mount Sinai Services Inc. (MSS) laboratory has successfully achieved ISO 15189 (OLA15189PLUS™) accreditation. MSS is one of very few independent clinical research laboratories in Canada to achieve this accreditation thereby providing their clients with strong assurance, compliance and added value […]

Read more

MSS now offers the Illumina verifi® prenatal test in Canada

Agreement Establishes Expanded Canadian Availability of verifi® Mount Sinai Services Inc. (Mount Sinai) a global provider of customized laboratory and research services, today announced a distribution agreement with Illumina, Inc. to provide the verifi® prenatal test(1) to pregnant women in Ontario who are at risk of having […]

Read more